LifeMD Is Maintained at Overweight by Keybanc

Dow JonesJan 9 04:46 · Ratings

KeyBanc Maintains LifeMD(LFMD.US) With Buy Rating, Cuts Target Price to $7

Futu NewsJan 8 20:34 · Ratings

KeyBanc Cuts Price Target on LifeMD to $7.50 From $10, Keeps Overweight Rating

MT NewswiresJan 8 20:26 · Ratings

Medifast Introduces New High-Protein Product Line OPTAVIA ASCEND For GLP-1 Users & Those Looking for Help to Keep Weight Off

BusinesswireJan 7 21:30

LifeMD Sets New CEO Compensation Strategy

TipRanksDec 31, 2024 22:28

Analysts Expect Breakeven For LifeMD, Inc. (NASDAQ:LFMD) Before Long

Yahoo FinanceDec 26, 2024 01:42